Using Simvastatin Mouthwash (0.6%, 1.2% and 1.8%) on the Improvement of Clinical Parameters in Patients with Chronic Periodontitis
| Autor: | Mohammad Azizian, Zahra Beigi, Ali Khorshidi, Zeinab Abdi, Sepideh Beigi, Mohammad-Ali Roozegar |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Periodontitis
medicine.medical_specialty Cholesterol medicine.medical_treatment Biology medicine.disease Placebo Gastroenterology Chronic periodontitis Bone remodeling chemistry.chemical_compound chemistry In vivo Simvastatin Internal medicine medicine Pharmacology (medical) Pharmacology Toxicology and Pharmaceutics (miscellaneous) Saline medicine.drug |
| Zdroj: | Research Journal of Pharmacy and Technology. 13:862 |
| ISSN: | 0974-360X 0974-3618 |
| DOI: | 10.5958/0974-360x.2020.00163.8 |
| Popis: | Periodontitis is a destructive disease that targets tooth supporting structures. Simvastatin (SMV) are inhibitors of HMG-COA reductase enzyme that have complex interaction with cholesterol metabolites, inflammatory mediators, hormones and bone metabolism, thus having direct and important effects on extent and severity of periodontitis. The present study aims to evaluate the in vivo effect of mouthwash of CHX and SMV (.6 and 1.2 and 1.8) as a local drug-delivery agent on clinical parameters in chronic periodontitis. 50 patients were selected and categorized into five treatment groups. At initial appointment SRP were done and clinical parameters were measured and mouthwashes of SMV (0.6-1.2-1.8) and CHX and placebo distributed among groups. Measurement of clinical parameters after one month repeated for all groups and required data was collected and analyzed. SRP with SMV (0.6 – 1.2 – 1.8) significantly improve the clinical parameters (AL-BOP-PD). Mouthwash of SMV 1.2 and 1.8 and CHX in decrease of BOP and PD and AL has no significant differences (P>0.05). Mouthwash of SMV 1.2 and 1.8 and CHX has significantly differences in decrease of BOP and PD than SMV.06 and placebo (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|